UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing Dilution
Piper Jaffray reiterated its Neutral rating on Exelixis (NASDAQ: EXEL) and reduced its price target from $5.50 to $4.50.
Piper Jaffray said, "Exelixis raised net proceeds of $120 million by issuing 30 million shares at $4.25 and $250 million from a 4.25% convertible note bringing proforma cash to $665 million. Cabozantinib has a November 29th PDUFA date in medullary thyroid cancer (MTC). Both the COMET-1 and COMET-2 pivotal studies are underway in castrate resistant prostate cancer (CRPC) plus 11 investigator sponsored trials (ISTs) under a CRADA funded by the NCI. … We are trimming our price target to $4.50 from $5.50 to account for dilution from the deals."
Exelixis closed at $4.38 on Friday.
Latest Ratings for EXEL
|Apr 2016||Stifel Nicolaus||Upgrades||Hold||Buy|
|Jan 2016||Leerink Swann||Upgrades||Market Perform||Outperform|
|Sep 2014||Stifel Nicolaus||Downgrades||Buy||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.